Rapid Micro Biosystems, Inc.
Rapid Micro Biosystems, Inc. (RPID) Stock Competitors & Peer Comparison
See (RPID) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RPID | $3.91 | -1.51% | 172.4M | -3.89 | -$1.00 | N/A |
| ABT | $114.02 | +1.63% | 195.3B | 30.16 | $3.72 | +2.13% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $381.92 | +2.48% | 145.5B | 45.15 | $8.42 | +0.89% |
| MDT | $98.36 | +0.79% | 124.3B | 26.47 | $3.66 | +2.92% |
| BSX | $74.52 | -1.58% | 110.6B | 38.43 | $1.94 | N/A |
| EW | $81.22 | +2.91% | 46.8B | 44.08 | $1.81 | N/A |
| BRKRP | $306.83 | +0.53% | 45.8B | N/A | N/A | +0.52% |
| PHG | $31.13 | +0.55% | 30B | 27.65 | $1.13 | +2.84% |
| DXCM | $74.12 | +2.56% | 28.5B | 34.97 | $2.09 | N/A |
Stock Comparison
RPID vs ABT Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, ABT has a market cap of 195.3B. Regarding current trading prices, RPID is priced at $3.91, while ABT trades at $114.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas ABT's P/E ratio is 30.16. In terms of profitability, RPID's ROE is -0.74%, compared to ABT's ROE of +0.13%. Regarding short-term risk, RPID is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check ABT's competition here
RPID vs BSX-PA Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, RPID is priced at $3.91, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, RPID's ROE is -0.74%, compared to BSX-PA's ROE of +0.13%. Regarding short-term risk, RPID is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check BSX-PA's competition here
RPID vs SYK Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, SYK has a market cap of 145.5B. Regarding current trading prices, RPID is priced at $3.91, while SYK trades at $381.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas SYK's P/E ratio is 45.15. In terms of profitability, RPID's ROE is -0.74%, compared to SYK's ROE of +0.15%. Regarding short-term risk, RPID is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check SYK's competition here
RPID vs MDT Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, MDT has a market cap of 124.3B. Regarding current trading prices, RPID is priced at $3.91, while MDT trades at $98.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas MDT's P/E ratio is 26.47. In terms of profitability, RPID's ROE is -0.74%, compared to MDT's ROE of +0.13%. Regarding short-term risk, RPID is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check MDT's competition here
RPID vs BSX Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, BSX has a market cap of 110.6B. Regarding current trading prices, RPID is priced at $3.91, while BSX trades at $74.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas BSX's P/E ratio is 38.43. In terms of profitability, RPID's ROE is -0.74%, compared to BSX's ROE of +0.13%. Regarding short-term risk, RPID is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check BSX's competition here
RPID vs EW Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, EW has a market cap of 46.8B. Regarding current trading prices, RPID is priced at $3.91, while EW trades at $81.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas EW's P/E ratio is 44.08. In terms of profitability, RPID's ROE is -0.74%, compared to EW's ROE of +0.10%. Regarding short-term risk, RPID is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check EW's competition here
RPID vs BRKRP Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, BRKRP has a market cap of 45.8B. Regarding current trading prices, RPID is priced at $3.91, while BRKRP trades at $306.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas BRKRP's P/E ratio is N/A. In terms of profitability, RPID's ROE is -0.74%, compared to BRKRP's ROE of -0.00%. Regarding short-term risk, RPID is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check BRKRP's competition here
RPID vs PHG Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, PHG has a market cap of 30B. Regarding current trading prices, RPID is priced at $3.91, while PHG trades at $31.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas PHG's P/E ratio is 27.65. In terms of profitability, RPID's ROE is -0.74%, compared to PHG's ROE of +0.08%. Regarding short-term risk, RPID is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check PHG's competition here
RPID vs DXCM Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, DXCM has a market cap of 28.5B. Regarding current trading prices, RPID is priced at $3.91, while DXCM trades at $74.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas DXCM's P/E ratio is 34.97. In terms of profitability, RPID's ROE is -0.74%, compared to DXCM's ROE of +0.32%. Regarding short-term risk, RPID is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check DXCM's competition here
RPID vs STE Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, STE has a market cap of 24.6B. Regarding current trading prices, RPID is priced at $3.91, while STE trades at $246.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas STE's P/E ratio is 34.92. In terms of profitability, RPID's ROE is -0.74%, compared to STE's ROE of +0.10%. Regarding short-term risk, RPID is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check STE's competition here
RPID vs ZBH Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, ZBH has a market cap of 19.6B. Regarding current trading prices, RPID is priced at $3.91, while ZBH trades at $98.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas ZBH's P/E ratio is 27.82. In terms of profitability, RPID's ROE is -0.74%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, RPID is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check ZBH's competition here
RPID vs ABMD Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, RPID is priced at $3.91, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas ABMD's P/E ratio is 65.36. In terms of profitability, RPID's ROE is -0.74%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, RPID is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check ABMD's competition here
RPID vs PODD Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, PODD has a market cap of 17B. Regarding current trading prices, RPID is priced at $3.91, while PODD trades at $246.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas PODD's P/E ratio is 70.32. In terms of profitability, RPID's ROE is -0.74%, compared to PODD's ROE of +0.17%. Regarding short-term risk, RPID is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check PODD's competition here
RPID vs SNN Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, SNN has a market cap of 15.8B. Regarding current trading prices, RPID is priced at $3.91, while SNN trades at $36.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas SNN's P/E ratio is 32.22. In terms of profitability, RPID's ROE is -0.74%, compared to SNN's ROE of +0.09%. Regarding short-term risk, RPID is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check SNN's competition here
RPID vs ALGN Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, ALGN has a market cap of 13.6B. Regarding current trading prices, RPID is priced at $3.91, while ALGN trades at $176.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas ALGN's P/E ratio is 33.63. In terms of profitability, RPID's ROE is -0.74%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, RPID is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check ALGN's competition here
RPID vs PEN Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, PEN has a market cap of 13.3B. Regarding current trading prices, RPID is priced at $3.91, while PEN trades at $339.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas PEN's P/E ratio is 80.98. In terms of profitability, RPID's ROE is -0.74%, compared to PEN's ROE of +0.13%. Regarding short-term risk, RPID is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check PEN's competition here
RPID vs SWAV Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, RPID is priced at $3.91, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas SWAV's P/E ratio is 78.76. In terms of profitability, RPID's ROE is -0.74%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, RPID is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check SWAV's competition here
RPID vs GMED Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, GMED has a market cap of 12.1B. Regarding current trading prices, RPID is priced at $3.91, while GMED trades at $92.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas GMED's P/E ratio is 29.32. In terms of profitability, RPID's ROE is -0.74%, compared to GMED's ROE of +0.10%. Regarding short-term risk, RPID is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check GMED's competition here
RPID vs BIO Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, BIO has a market cap of 7.3B. Regarding current trading prices, RPID is priced at $3.91, while BIO trades at $269.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas BIO's P/E ratio is 9.74. In terms of profitability, RPID's ROE is -0.74%, compared to BIO's ROE of +0.11%. Regarding short-term risk, RPID is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check BIO's competition here
RPID vs BIO-B Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, BIO-B has a market cap of 7.1B. Regarding current trading prices, RPID is priced at $3.91, while BIO-B trades at $266.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas BIO-B's P/E ratio is 9.40. In terms of profitability, RPID's ROE is -0.74%, compared to BIO-B's ROE of +0.11%. Regarding short-term risk, RPID is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check BIO-B's competition here
RPID vs GKOS Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, GKOS has a market cap of 6.9B. Regarding current trading prices, RPID is priced at $3.91, while GKOS trades at $118.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas GKOS's P/E ratio is -80.81. In terms of profitability, RPID's ROE is -0.74%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, RPID is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check GKOS's competition here
RPID vs BRKR Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, BRKR has a market cap of 5.8B. Regarding current trading prices, RPID is priced at $3.91, while BRKR trades at $39.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas BRKR's P/E ratio is -255.20. In terms of profitability, RPID's ROE is -0.74%, compared to BRKR's ROE of -0.00%. Regarding short-term risk, RPID is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check BRKR's competition here
RPID vs IRTC Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, IRTC has a market cap of 4.9B. Regarding current trading prices, RPID is priced at $3.91, while IRTC trades at $139.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas IRTC's P/E ratio is -93.19. In terms of profitability, RPID's ROE is -0.74%, compared to IRTC's ROE of -0.38%. Regarding short-term risk, RPID is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check IRTC's competition here
RPID vs NARI Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, RPID is priced at $3.91, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas NARI's P/E ratio is -59.24. In terms of profitability, RPID's ROE is -0.74%, compared to NARI's ROE of -0.00%. Regarding short-term risk, RPID is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check NARI's competition here
RPID vs TMDX Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, TMDX has a market cap of 4.6B. Regarding current trading prices, RPID is priced at $3.91, while TMDX trades at $132.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas TMDX's P/E ratio is 53.06. In terms of profitability, RPID's ROE is -0.74%, compared to TMDX's ROE of +0.31%. Regarding short-term risk, RPID is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check TMDX's competition here
RPID vs LIVN Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, LIVN has a market cap of 3.7B. Regarding current trading prices, RPID is priced at $3.91, while LIVN trades at $66.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas LIVN's P/E ratio is -17.19. In terms of profitability, RPID's ROE is -0.74%, compared to LIVN's ROE of -0.19%. Regarding short-term risk, RPID is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check LIVN's competition here
RPID vs AXNX Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, RPID is priced at $3.91, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas AXNX's P/E ratio is -709.80. In terms of profitability, RPID's ROE is -0.74%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, RPID is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check AXNX's competition here
RPID vs ITGR Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, RPID is priced at $3.91, while ITGR trades at $85.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas ITGR's P/E ratio is 34.93. In terms of profitability, RPID's ROE is -0.74%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, RPID is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check ITGR's competition here
RPID vs ESTA Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, RPID is priced at $3.91, while ESTA trades at $75.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas ESTA's P/E ratio is -26.76. In terms of profitability, RPID's ROE is -0.74%, compared to ESTA's ROE of -2.54%. Regarding short-term risk, RPID is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check ESTA's competition here
RPID vs NUVA Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, RPID is priced at $3.91, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas NUVA's P/E ratio is 75.00. In terms of profitability, RPID's ROE is -0.74%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, RPID is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check NUVA's competition here
RPID vs PMI Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, PMI has a market cap of 2B. Regarding current trading prices, RPID is priced at $3.91, while PMI trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas PMI's P/E ratio is -2.84. In terms of profitability, RPID's ROE is -0.74%, compared to PMI's ROE of +1.64%. Regarding short-term risk, RPID is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check PMI's competition here
RPID vs ATEC Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, ATEC has a market cap of 1.9B. Regarding current trading prices, RPID is priced at $3.91, while ATEC trades at $12.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas ATEC's P/E ratio is -12.51. In terms of profitability, RPID's ROE is -0.74%, compared to ATEC's ROE of -103.69%. Regarding short-term risk, RPID is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check ATEC's competition here
RPID vs AORT Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, AORT has a market cap of 1.8B. Regarding current trading prices, RPID is priced at $3.91, while AORT trades at $37.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas AORT's P/E ratio is 182.64. In terms of profitability, RPID's ROE is -0.74%, compared to AORT's ROE of +0.02%. Regarding short-term risk, RPID is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check AORT's competition here
RPID vs UFPT Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, RPID is priced at $3.91, while UFPT trades at $236.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas UFPT's P/E ratio is 27.15. In terms of profitability, RPID's ROE is -0.74%, compared to UFPT's ROE of +0.18%. Regarding short-term risk, RPID is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check UFPT's competition here
RPID vs AXGN Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, AXGN has a market cap of 1.8B. Regarding current trading prices, RPID is priced at $3.91, while AXGN trades at $35.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas AXGN's P/E ratio is -706.00. In terms of profitability, RPID's ROE is -0.74%, compared to AXGN's ROE of -0.02%. Regarding short-term risk, RPID is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check AXGN's competition here
RPID vs INSP Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, RPID is priced at $3.91, while INSP trades at $58.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas INSP's P/E ratio is 12.19. In terms of profitability, RPID's ROE is -0.74%, compared to INSP's ROE of +0.21%. Regarding short-term risk, RPID is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check INSP's competition here
RPID vs TNDM Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, TNDM has a market cap of 1.7B. Regarding current trading prices, RPID is priced at $3.91, while TNDM trades at $27.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas TNDM's P/E ratio is -8.11. In terms of profitability, RPID's ROE is -0.74%, compared to TNDM's ROE of -1.20%. Regarding short-term risk, RPID is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check TNDM's competition here
RPID vs PRCT Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, RPID is priced at $3.91, while PRCT trades at $26.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas PRCT's P/E ratio is -17.82. In terms of profitability, RPID's ROE is -0.74%, compared to PRCT's ROE of -0.22%. Regarding short-term risk, RPID is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check PRCT's competition here
RPID vs AHCO Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, AHCO has a market cap of 1.4B. Regarding current trading prices, RPID is priced at $3.91, while AHCO trades at $10.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas AHCO's P/E ratio is 18.80. In terms of profitability, RPID's ROE is -0.74%, compared to AHCO's ROE of +0.05%. Regarding short-term risk, RPID is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check AHCO's competition here
RPID vs CNMD Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, RPID is priced at $3.91, while CNMD trades at $45.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas CNMD's P/E ratio is 29.90. In terms of profitability, RPID's ROE is -0.74%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, RPID is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check CNMD's competition here
RPID vs LMRI Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, LMRI has a market cap of 1.4B. Regarding current trading prices, RPID is priced at $3.91, while LMRI trades at $15.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas LMRI's P/E ratio is -31.63. In terms of profitability, RPID's ROE is -0.74%, compared to LMRI's ROE of -0.52%. Regarding short-term risk, RPID is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check LMRI's competition here
RPID vs IRMD Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, IRMD has a market cap of 1.3B. Regarding current trading prices, RPID is priced at $3.91, while IRMD trades at $100.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas IRMD's P/E ratio is 59.18. In terms of profitability, RPID's ROE is -0.74%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, RPID is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check IRMD's competition here
RPID vs HSKA Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, RPID is priced at $3.91, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas HSKA's P/E ratio is -62.49. In terms of profitability, RPID's ROE is -0.74%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, RPID is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check HSKA's competition here
RPID vs SILK Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, RPID is priced at $3.91, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas SILK's P/E ratio is -18.96. In terms of profitability, RPID's ROE is -0.74%, compared to SILK's ROE of -0.35%. Regarding short-term risk, RPID is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check SILK's competition here
RPID vs FNA Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, RPID is priced at $3.91, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas FNA's P/E ratio is -19.83. In terms of profitability, RPID's ROE is -0.74%, compared to FNA's ROE of -0.17%. Regarding short-term risk, RPID is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check FNA's competition here
RPID vs INMD Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, INMD has a market cap of 964.3M. Regarding current trading prices, RPID is priced at $3.91, while INMD trades at $14.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas INMD's P/E ratio is 10.21. In terms of profitability, RPID's ROE is -0.74%, compared to INMD's ROE of +0.15%. Regarding short-term risk, RPID is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check INMD's competition here
RPID vs SSII Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, SSII has a market cap of 959.4M. Regarding current trading prices, RPID is priced at $3.91, while SSII trades at $4.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas SSII's P/E ratio is -82.58. In terms of profitability, RPID's ROE is -0.74%, compared to SSII's ROE of -0.50%. Regarding short-term risk, RPID is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check SSII's competition here
RPID vs IART Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, IART has a market cap of 951.1M. Regarding current trading prices, RPID is priced at $3.91, while IART trades at $11.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas IART's P/E ratio is -1.89. In terms of profitability, RPID's ROE is -0.74%, compared to IART's ROE of -0.39%. Regarding short-term risk, RPID is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check IART's competition here
RPID vs CSII Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, RPID is priced at $3.91, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas CSII's P/E ratio is -20.83. In terms of profitability, RPID's ROE is -0.74%, compared to CSII's ROE of -0.14%. Regarding short-term risk, RPID is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check CSII's competition here
RPID vs BFLY Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, BFLY has a market cap of 754M. Regarding current trading prices, RPID is priced at $3.91, while BFLY trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas BFLY's P/E ratio is -9.05. In terms of profitability, RPID's ROE is -0.74%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, RPID is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check BFLY's competition here
RPID vs CBLL Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, CBLL has a market cap of 750.1M. Regarding current trading prices, RPID is priced at $3.91, while CBLL trades at $19.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas CBLL's P/E ratio is -5.51. In terms of profitability, RPID's ROE is -0.74%, compared to CBLL's ROE of -0.30%. Regarding short-term risk, RPID is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check CBLL's competition here
RPID vs CRY Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, RPID is priced at $3.91, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas CRY's P/E ratio is 425.71. In terms of profitability, RPID's ROE is -0.74%, compared to CRY's ROE of +0.02%. Regarding short-term risk, RPID is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check CRY's competition here
RPID vs AVNS Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, AVNS has a market cap of 718.1M. Regarding current trading prices, RPID is priced at $3.91, while AVNS trades at $15.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas AVNS's P/E ratio is -1.52. In terms of profitability, RPID's ROE is -0.74%, compared to AVNS's ROE of -0.58%. Regarding short-term risk, RPID is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check AVNS's competition here
RPID vs SIBN Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, SIBN has a market cap of 671.7M. Regarding current trading prices, RPID is priced at $3.91, while SIBN trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas SIBN's P/E ratio is -30.35. In terms of profitability, RPID's ROE is -0.74%, compared to SIBN's ROE of -0.13%. Regarding short-term risk, RPID is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check SIBN's competition here
RPID vs TCMD Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, TCMD has a market cap of 641.5M. Regarding current trading prices, RPID is priced at $3.91, while TCMD trades at $28.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas TCMD's P/E ratio is 44.18. In terms of profitability, RPID's ROE is -0.74%, compared to TCMD's ROE of +0.09%. Regarding short-term risk, RPID is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check TCMD's competition here
RPID vs SRDX Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, RPID is priced at $3.91, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas SRDX's P/E ratio is -34.66. In terms of profitability, RPID's ROE is -0.74%, compared to SRDX's ROE of -0.16%. Regarding short-term risk, RPID is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check SRDX's competition here
RPID vs APEN Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, RPID is priced at $3.91, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas APEN's P/E ratio is -9.43. In terms of profitability, RPID's ROE is -0.74%, compared to APEN's ROE of -0.85%. Regarding short-term risk, RPID is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check APEN's competition here
RPID vs BVS Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, BVS has a market cap of 574.7M. Regarding current trading prices, RPID is priced at $3.91, while BVS trades at $8.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas BVS's P/E ratio is 53.63. In terms of profitability, RPID's ROE is -0.74%, compared to BVS's ROE of +0.05%. Regarding short-term risk, RPID is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check BVS's competition here
RPID vs VREX Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, VREX has a market cap of 569.7M. Regarding current trading prices, RPID is priced at $3.91, while VREX trades at $13.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas VREX's P/E ratio is -8.29. In terms of profitability, RPID's ROE is -0.74%, compared to VREX's ROE of -0.14%. Regarding short-term risk, RPID is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check VREX's competition here
RPID vs CTKB Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, CTKB has a market cap of 566.4M. Regarding current trading prices, RPID is priced at $3.91, while CTKB trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas CTKB's P/E ratio is -40.27. In terms of profitability, RPID's ROE is -0.74%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, RPID is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check CTKB's competition here
RPID vs OFIX Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, OFIX has a market cap of 549.2M. Regarding current trading prices, RPID is priced at $3.91, while OFIX trades at $13.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas OFIX's P/E ratio is -4.58. In terms of profitability, RPID's ROE is -0.74%, compared to OFIX's ROE of -0.26%. Regarding short-term risk, RPID is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check OFIX's competition here
RPID vs ZIMV Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, RPID is priced at $3.91, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, RPID's ROE is -0.74%, compared to ZIMV's ROE of -0.05%. Regarding short-term risk, RPID is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check ZIMV's competition here
RPID vs BWAY Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, BWAY has a market cap of 487.3M. Regarding current trading prices, RPID is priced at $3.91, while BWAY trades at $23.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas BWAY's P/E ratio is 83.17. In terms of profitability, RPID's ROE is -0.74%, compared to BWAY's ROE of +0.09%. Regarding short-term risk, RPID is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check BWAY's competition here
RPID vs PACB Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, PACB has a market cap of 486.1M. Regarding current trading prices, RPID is priced at $3.91, while PACB trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas PACB's P/E ratio is -0.88. In terms of profitability, RPID's ROE is -0.74%, compared to PACB's ROE of -11.23%. Regarding short-term risk, RPID is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check PACB's competition here
RPID vs NPCE Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, NPCE has a market cap of 477.6M. Regarding current trading prices, RPID is priced at $3.91, while NPCE trades at $14.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas NPCE's P/E ratio is -19.12. In terms of profitability, RPID's ROE is -0.74%, compared to NPCE's ROE of -1.37%. Regarding short-term risk, RPID is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check NPCE's competition here
RPID vs CERS Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, CERS has a market cap of 462.9M. Regarding current trading prices, RPID is priced at $3.91, while CERS trades at $2.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas CERS's P/E ratio is -30.12. In terms of profitability, RPID's ROE is -0.74%, compared to CERS's ROE of -0.28%. Regarding short-term risk, RPID is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check CERS's competition here
RPID vs LAB Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, LAB has a market cap of 434.6M. Regarding current trading prices, RPID is priced at $3.91, while LAB trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas LAB's P/E ratio is -2.90. In terms of profitability, RPID's ROE is -0.74%, compared to LAB's ROE of -0.29%. Regarding short-term risk, RPID is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check LAB's competition here
RPID vs KIDS Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, KIDS has a market cap of 425.3M. Regarding current trading prices, RPID is priced at $3.91, while KIDS trades at $16.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas KIDS's P/E ratio is -8.65. In terms of profitability, RPID's ROE is -0.74%, compared to KIDS's ROE of -0.13%. Regarding short-term risk, RPID is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check KIDS's competition here
RPID vs CATX Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, CATX has a market cap of 421.5M. Regarding current trading prices, RPID is priced at $3.91, while CATX trades at $5.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas CATX's P/E ratio is -3.75. In terms of profitability, RPID's ROE is -0.74%, compared to CATX's ROE of -0.39%. Regarding short-term risk, RPID is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check CATX's competition here
RPID vs CLPT Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, CLPT has a market cap of 420.9M. Regarding current trading prices, RPID is priced at $3.91, while CLPT trades at $13.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas CLPT's P/E ratio is -17.05. In terms of profitability, RPID's ROE is -0.74%, compared to CLPT's ROE of -1.14%. Regarding short-term risk, RPID is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check CLPT's competition here
RPID vs RXST Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, RXST has a market cap of 354.8M. Regarding current trading prices, RPID is priced at $3.91, while RXST trades at $8.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas RXST's P/E ratio is -9.81. In terms of profitability, RPID's ROE is -0.74%, compared to RXST's ROE of -0.13%. Regarding short-term risk, RPID is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check RXST's competition here
RPID vs DCTH Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, DCTH has a market cap of 339.4M. Regarding current trading prices, RPID is priced at $3.91, while DCTH trades at $9.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas DCTH's P/E ratio is 326.00. In terms of profitability, RPID's ROE is -0.74%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, RPID is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check DCTH's competition here
RPID vs SENS Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, SENS has a market cap of 333.4M. Regarding current trading prices, RPID is priced at $3.91, while SENS trades at $8.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas SENS's P/E ratio is -5.30. In terms of profitability, RPID's ROE is -0.74%, compared to SENS's ROE of -1.35%. Regarding short-term risk, RPID is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check SENS's competition here
RPID vs VMD Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, VMD has a market cap of 319.6M. Regarding current trading prices, RPID is priced at $3.91, while VMD trades at $8.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas VMD's P/E ratio is 24.24. In terms of profitability, RPID's ROE is -0.74%, compared to VMD's ROE of +0.10%. Regarding short-term risk, RPID is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check VMD's competition here
RPID vs SMLR Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, RPID is priced at $3.91, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas SMLR's P/E ratio is 3.92. In terms of profitability, RPID's ROE is -0.74%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, RPID is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check SMLR's competition here
RPID vs SGHT Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, SGHT has a market cap of 285.5M. Regarding current trading prices, RPID is priced at $3.91, while SGHT trades at $5.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas SGHT's P/E ratio is -6.00. In terms of profitability, RPID's ROE is -0.74%, compared to SGHT's ROE of -0.62%. Regarding short-term risk, RPID is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check SGHT's competition here
RPID vs QTRX Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, QTRX has a market cap of 269.1M. Regarding current trading prices, RPID is priced at $3.91, while QTRX trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas QTRX's P/E ratio is -2.46. In terms of profitability, RPID's ROE is -0.74%, compared to QTRX's ROE of -0.31%. Regarding short-term risk, RPID is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check QTRX's competition here
RPID vs MGRM Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, RPID is priced at $3.91, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas MGRM's P/E ratio is -11.11. In terms of profitability, RPID's ROE is -0.74%, compared to MGRM's ROE of -1.37%. Regarding short-term risk, RPID is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check MGRM's competition here
RPID vs MASS Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, MASS has a market cap of 241.4M. Regarding current trading prices, RPID is priced at $3.91, while MASS trades at $6.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas MASS's P/E ratio is -3.22. In terms of profitability, RPID's ROE is -0.74%, compared to MASS's ROE of -0.03%. Regarding short-term risk, RPID is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check MASS's competition here
RPID vs NVRO Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, RPID is priced at $3.91, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas NVRO's P/E ratio is -1.91. In terms of profitability, RPID's ROE is -0.74%, compared to NVRO's ROE of -0.27%. Regarding short-term risk, RPID is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check NVRO's competition here
RPID vs PROF Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, PROF has a market cap of 210.2M. Regarding current trading prices, RPID is priced at $3.91, while PROF trades at $7.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas PROF's P/E ratio is -5.27. In terms of profitability, RPID's ROE is -0.74%, compared to PROF's ROE of -0.92%. Regarding short-term risk, RPID is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check PROF's competition here
RPID vs EYES Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, RPID is priced at $3.91, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas EYES's P/E ratio is N/A. In terms of profitability, RPID's ROE is -0.74%, compared to EYES's ROE of -4.16%. Regarding short-term risk, RPID is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check EYES's competition here
RPID vs SNWV Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, SNWV has a market cap of 208M. Regarding current trading prices, RPID is priced at $3.91, while SNWV trades at $24.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas SNWV's P/E ratio is -33.22. In terms of profitability, RPID's ROE is -0.74%, compared to SNWV's ROE of +0.59%. Regarding short-term risk, RPID is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check SNWV's competition here
RPID vs ELMD Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, ELMD has a market cap of 203.2M. Regarding current trading prices, RPID is priced at $3.91, while ELMD trades at $24.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas ELMD's P/E ratio is 23.65. In terms of profitability, RPID's ROE is -0.74%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, RPID is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check ELMD's competition here
RPID vs BSGM Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, RPID is priced at $3.91, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas BSGM's P/E ratio is -5.81. In terms of profitability, RPID's ROE is -0.74%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, RPID is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check BSGM's competition here
RPID vs AVR Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, AVR has a market cap of 186.9M. Regarding current trading prices, RPID is priced at $3.91, while AVR trades at $6.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas AVR's P/E ratio is -2.18. In terms of profitability, RPID's ROE is -0.74%, compared to AVR's ROE of -2.51%. Regarding short-term risk, RPID is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check AVR's competition here
RPID vs OWLT Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, OWLT has a market cap of 181.5M. Regarding current trading prices, RPID is priced at $3.91, while OWLT trades at $10.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas OWLT's P/E ratio is -4.04. In terms of profitability, RPID's ROE is -0.74%, compared to OWLT's ROE of +1.27%. Regarding short-term risk, RPID is more volatile compared to OWLT. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check OWLT's competition here
RPID vs TLSI Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, TLSI has a market cap of 180.1M. Regarding current trading prices, RPID is priced at $3.91, while TLSI trades at $5.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas TLSI's P/E ratio is -2.57. In terms of profitability, RPID's ROE is -0.74%, compared to TLSI's ROE of +1.49%. Regarding short-term risk, RPID is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check TLSI's competition here
RPID vs MDGS Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, RPID is priced at $3.91, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas MDGS's P/E ratio is -0.27. In terms of profitability, RPID's ROE is -0.74%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, RPID is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check MDGS's competition here
RPID vs EDAP Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, EDAP has a market cap of 176.1M. Regarding current trading prices, RPID is priced at $3.91, while EDAP trades at $4.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas EDAP's P/E ratio is -8.26. In terms of profitability, RPID's ROE is -0.74%, compared to EDAP's ROE of -0.62%. Regarding short-term risk, RPID is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check EDAP's competition here
RPID vs CVRX Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, CVRX has a market cap of 160.8M. Regarding current trading prices, RPID is priced at $3.91, while CVRX trades at $6.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas CVRX's P/E ratio is -3.00. In terms of profitability, RPID's ROE is -0.74%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, RPID is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check CVRX's competition here
RPID vs QIPT Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, QIPT has a market cap of 160.5M. Regarding current trading prices, RPID is priced at $3.91, while QIPT trades at $3.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas QIPT's P/E ratio is -15.70. In terms of profitability, RPID's ROE is -0.74%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, RPID is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check QIPT's competition here
RPID vs INGN Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, INGN has a market cap of 157.2M. Regarding current trading prices, RPID is priced at $3.91, while INGN trades at $5.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas INGN's P/E ratio is -5.79. In terms of profitability, RPID's ROE is -0.74%, compared to INGN's ROE of -0.13%. Regarding short-term risk, RPID is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check INGN's competition here
RPID vs APYX Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, APYX has a market cap of 155.1M. Regarding current trading prices, RPID is priced at $3.91, while APYX trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas APYX's P/E ratio is -10.50. In terms of profitability, RPID's ROE is -0.74%, compared to APYX's ROE of -1.54%. Regarding short-term risk, RPID is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check APYX's competition here
RPID vs NNOX Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, NNOX has a market cap of 154.9M. Regarding current trading prices, RPID is priced at $3.91, while NNOX trades at $2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas NNOX's P/E ratio is -2.76. In terms of profitability, RPID's ROE is -0.74%, compared to NNOX's ROE of -0.32%. Regarding short-term risk, RPID is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check NNOX's competition here
RPID vs ANIK Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, ANIK has a market cap of 153.3M. Regarding current trading prices, RPID is priced at $3.91, while ANIK trades at $10.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas ANIK's P/E ratio is -10.74. In terms of profitability, RPID's ROE is -0.74%, compared to ANIK's ROE of -0.22%. Regarding short-term risk, RPID is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check ANIK's competition here
RPID vs QTI Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, QTI has a market cap of 149.5M. Regarding current trading prices, RPID is priced at $3.91, while QTI trades at $5.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas QTI's P/E ratio is -2.28. In terms of profitability, RPID's ROE is -0.74%, compared to QTI's ROE of +1.72%. Regarding short-term risk, RPID is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check QTI's competition here
RPID vs LNSR Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, LNSR has a market cap of 139.6M. Regarding current trading prices, RPID is priced at $3.91, while LNSR trades at $11.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas LNSR's P/E ratio is -2.68. In terms of profitability, RPID's ROE is -0.74%, compared to LNSR's ROE of +5.33%. Regarding short-term risk, RPID is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for RPID.Check LNSR's competition here
RPID vs LUCD Comparison February 2026
RPID plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RPID stands at 172.4M. In comparison, LUCD has a market cap of 138.4M. Regarding current trading prices, RPID is priced at $3.91, while LUCD trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RPID currently has a P/E ratio of -3.89, whereas LUCD's P/E ratio is -1.77. In terms of profitability, RPID's ROE is -0.74%, compared to LUCD's ROE of -6.32%. Regarding short-term risk, RPID is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for RPID.Check LUCD's competition here